Lipocine Inc.
NASDAQ Capital MarketTotal Valuation
Lipocine Inc. carries a market capitalization of 20.20M, placing it among publicly traded companies globally. Its enterprise value stands at -2.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.20M |
| Enterprise Value | -2.16M |
Share Statistics
Lipocine Inc. currently has 8.24M shares outstanding.
| Shares Outstanding | 8.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11.11, and the price-to-book ratio stands at 0.97.
| PE Ratio | N/A |
| PS Ratio | 11.11 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | -1.56 |
| P/OCF Ratio | -1.56 |
Enterprise Valuation
| EV / Sales | 35.02 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lipocine Inc. maintains a current ratio of 11.48, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.48 |
| Quick Ratio | 11.39 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -60.94 |
| Return on Assets (ROA) | -55.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 200.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Lipocine Inc.'s stock has declined approximately -15.22491% over the past 52 weeks. The 50-day moving average sits at 2.23, while the 200-day moving average is 4.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | -15.22491% |
| 50-Day Moving Average | 2.23 |
| 200-Day Moving Average | 4.51 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lipocine Inc. generated 1.57M in revenue and converted that into -11.85M in net income, yielding earnings per share of -1.74. EBITDA reached -12.51M, while operating income came in at -12.57M.
| Revenue | 1.57M |
| Gross Profit | -1.85M |
| Operating Income | -12.57M |
| Pretax Income | -11.85M |
| Net Income | -11.85M |
| EBITDA | -12.51M |
| EBIT | -12.57M |
| Earnings Per Share (EPS) | -1.74 |
Balance Sheet
Total book value stands at 21.77M, with working capital of 21.67M providing operational flexibility.
| Cash & Cash Equivalents | 23.27M |
| Total Debt | N/A |
| Net Debt | -4.98M |
| Equity (Book Value) | 21.77M |
| Book Value Per Share | 2.64 |
| Working Capital | 21.67M |
Cash Flow
Lipocine Inc. produced -11.19M in operating cash flow over the past twelve months.
| Operating Cash Flow | -11.19M |
| Capital Expenditures | N/A |
| Free Cash Flow | -11.19M |
| FCF Per Share | -1.64 |
Margins
Lipocine Inc. operates with a gross margin of -30.07, reflecting its pricing power and cost economics. The operating margin of -800.82 and net profit margin of -755.13 provide insight into operational efficiency.
| Gross Margin | -30.07 |
| Operating Margin | -800.82 |
| Pretax Margin | -755.11 |
| Profit Margin | -755.13 |
| EBITDA Margin | -797.09 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -77.10 |
| FCF Yield | -64.21 |
Stock Splits
Lipocine Inc.'s most recent stock split took place on May 12, 2023 with a 17:1 split ratio.
| Last Split Date | 5/12/2023 |
| Split Ratio | 17:1 |
Scores
Lipocine Inc. posts an Altman Z-Score of -7.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.13 |